Pilot Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas

Trial Profile

Pilot Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 01 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 14 Aug 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top